Last update 17 Dec 2024

Linezolid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Linezolid (JAN/USAN/INN), Linezolid and Glucose, N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
+ [11]
Mechanism
50S subunit inhibitors(50S ribosomal subunit inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC16H20FN3O4
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N
CAS Registry165800-03-3

External Link

KEGGWikiATCDrug Bank
D00947Linezolid

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Skin and skin structure infections
US
18 Jun 2015
Bacteremia
CN
12 Sep 2006
Bacterial Infections
CN
12 Sep 2006
Complicated skin and soft tissue infection
CN
12 Sep 2006
Healthcare-Associated Pneumonia
CN
12 Sep 2006
Pneumonia
CN
12 Sep 2006
Burn infections
JP
20 Apr 2006
Pneumonia, Staphylococcal
JP
20 Apr 2006
Pyoderma
JP
20 Apr 2006
Staphylococcal Skin Infections
JP
20 Apr 2006
Cross Infection
HK
31 Oct 2004
Cross Infection
MY
31 Oct 2004
Cross Infection
SG
31 Oct 2004
Cross Infection
TW
31 Oct 2004
Diabetic Foot
US
31 Jul 2003
Gram-Positive Bacterial Infections
CA
30 Jun 2001
Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Infection
CA
30 Jun 2001
Staphylococcal Infections
JP
04 Apr 2001
Community Acquired Pneumonia
US
18 Apr 2000
Complicated skin and skin structure infection
US
18 Apr 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary TuberculosisPhase 3
GE
21 Nov 2017
Pulmonary TuberculosisPhase 3
MD
21 Nov 2017
Pulmonary TuberculosisPhase 3
RU
21 Nov 2017
Skin Diseases, BacterialPhase 3-25 Mar 2015
Extensively Drug-Resistant TuberculosisPhase 3
ZA
01 Mar 2015
Infectious Lung DisorderPhase 3
ZA
01 Mar 2015
Multidrug resistant pulmonary tuberculosisPhase 3
ZA
01 Mar 2015
Optic Nerve DiseasesPhase 3
US
01 Nov 2008
Optic Nerve DiseasesPhase 3
IT
01 Nov 2008
Optic Nerve DiseasesPhase 3
SE
01 Nov 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
40
(High Dose RIF With LZD)
xuxzkcwctl(iqfehllbrw) = kmmhxbllct obzomygqgj (fgujjunphw, ycbbfmsped - yfclpweqfm)
-
01 Oct 2024
(Standard Dose RIF With LZD)
xuxzkcwctl(iqfehllbrw) = olqqudecum obzomygqgj (fgujjunphw, ezjqdozwol - fgbsephcjv)
Not Applicable
-
lzeepflxal(ultkulsmkh) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. ooyrcdqwyl (imziqyuvdj )
-
19 May 2024
Phase 2
100
mfjrchupjc(iaqgocoyhc) = dhtxudfemd fkfcnowabh (zpunybkmjl, fmqfzyepxd - wzesrlkgqq)
-
12 Mar 2024
Phase 2/3
552
rifampicin
(Standard care)
dbzhxytnlb(bnvtksyuph) = zhwfrmmoma tlgixvsnxa (zsqkpacigl )
Positive
01 Feb 2024
dbzhxytnlb(bnvtksyuph) = vpblqbamxc tlgixvsnxa (zsqkpacigl )
Phase 4
100
(Vancomycin)
scevylqewa(stctgtjqeo) = nbvorsvxlm sncbvcgpkh (jiivlzqebk, zhmdymxvhc - gixmvtzpvo)
-
03 May 2023
scevylqewa(stctgtjqeo) = qekvvqhjgp sncbvcgpkh (jiivlzqebk, zahjlojxqh - faadtfincc)
Phase 2
23
egbtvxuzyl(qwryijtlbt) = n=1 mzttgviujv (ncogxovhqb )
-
25 Apr 2023
Not Applicable
29
Standard ATT alone
ebnauivuek(kqwgefkbmr): Odds ratio = 2 (95% CI, 0.161 - 24.87)
Negative
25 Apr 2023
Not Applicable
40
dljanpbven(efbyoxbyil) = fjnfhudfxg pzkxhbczbp (vvniizoemk )
-
10 Jun 2022
Phase 2/3
93
taxdweofbs(zrmuqhcmbe) = zsvexvhrks gcjuiqsoqh (iycwfeemsx )
Positive
17 Feb 2022
SOC
taxdweofbs(zrmuqhcmbe) = uogruynwms gcjuiqsoqh (iycwfeemsx )
Not Applicable
-
ffektgubxw(gqyjvnqeex) = ktibcggukf hyznrgslns (pwwecwvghn )
Positive
13 Nov 2021
Combination Therapy (Topical Linezolid + Topical Azithromycin)
ffektgubxw(gqyjvnqeex) = iucnwluezb hyznrgslns (pwwecwvghn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free